Predictors of androgen independence in metastatic prostate cancer

BJU International

Volumn 93, Issue 9, 2004, Pages 1221-1224

  Sim, H G ^a   Lau, W K O ^a   Cheng, C W S ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Advanced prostate cancer; Hormone refractory; Metastases; PSA nadir

Indexed keywords

ANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BONE DISEASE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; SCORING SYSTEM; SPINAL CORD COMPRESSION; STATISTICAL ANALYSIS; BLOOD; DISEASE COURSE; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; PROSTATE TUMOR; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 2942726491     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04863.x     Document Type: Article

References (16)

1. Hamilton M, Dahut W, Brawley O et al. A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer. Acta Oncol 2003; 42: 195-201
2. Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003; 88: 822-7
3. Millikan R, Thall PF, Lee SJ et al. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol 2003; 21: 878-83
4. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 2003; 97: 2988-94
5. Fleming ID, Cooper JS, Henson DE et al. eds. AJCC. Manual for Staging of Cancer, 5th edn. Philadelphia: Lippincott-Raven, 1997
6. Gleason DF, Mellinger GT. Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 1974; 111: 58-64
7. Soloway MS, Ishikawa S, van der Zwaag R, Todd B. Prognostic factors in patients with advanced prostate cancer. Urology 1989 May; 33 (Suppl. 5): 53-6
8. Ishikawa S, Soloway MS, Van der Zwaag R, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989; 141: 1139-42
9. Chia KSA, Seow Lee HP, Shanmugaratnam K. Cancer incidence in Singapore 1993-97. Singapore Cancer Registry Report no. 5. Singapore: Singapore Cancer Registry, 2000
10. Benaim EA, Pace CM, Lam PM, Roehrborn CG. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 2002; 59: 73-8
11. Benaim EA, Pace CM, Roehrborn CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urol 2002; 42: 12-7
12. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormonal therapy for prostate cancer. J Urol 2002; 168: 995-1000
13. Calvo BF, Levine AM, Marcos M et al. Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 2003; 9: 1087-97
14. Segawa N, Nakamura M, Shan L et al. Expression and somatic mutation on androgen receptor gene in prostate cancer. Int J Urol 2002; 9: 545-53
15. Glynne-Jones E, Harper ME, Seery LT et al. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer 2001; 94: 178-84
16. Dunsmuir WD, Gillett CE, Meyer LC et al. Molecular markers for predicting prostate cancer stage and survival. BJU Int 2000; 86: 869-78